RBC Capital raised the firm’s price target on CorMedix to $10 from $6 and keeps an Outperform rating on the shares. The company reported Q3 “with optimism” heading into its key DefenCath PDUFA in catheter-related blood stream infections prevention in hemodialysis, the analyst tells investors in a research note. All signals appeared positive on the prospects of an approval outcome, which is now seen as increasingly likely this time around, the firm added.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CRMD:
- CorMedix Inc. Announces FDA Approval of DefenCath® to Reduce the Incidence of Catheter-Related Bloodstream Infections in Adult Hemodialysis Patients
- CorMedix reports Q3 EPS (17c), consensus (21c)
- CorMedix Inc. Reports Third Quarter and Nine Month 2023 Financial Results and Provides Business Update
- CorMedix options imply 36.0% move in share price post-earnings
- CorMedix Inc. to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on November 14, 2023